Three Trajectories Identified in Preclinical Progression in Alzheimer Disease

TUESDAY, May 5, 2026 (HealthDay News) -- Three trajectories of preclinical progression have been identified in Alzheimer disease, according to a study published online April 21 in Alzheimer's & Dementia.Runpeng Li, Ph.D., from the University of Southern California in San Diego, and colleagues used data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Study and the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Study, which enrolled amyloid beta (Aβ)-positive and Aβ-negative individuals, to identify subgroups of cognitive decline and predictors of heterogeneity in preclinical progression.The researchers identified three trajectory classes: stable, slow decliners, and fast decliners. There was an association for higher phosphorylated tau at 217, smaller hippocampal volume, and elevated tau positron emission tomography with declining classes. Of the Aβ-positive individuals, about 70 percent were stable."These results suggest we may need to rethink how we design clinical trials in preclinical Alzheimer's disease," Li said in a statement. "Many people with Alzheimer's remain stable over the course of a study, which can make it hard to tell if a treatment is working. Identifying those who are more likely to decline could make trials more efficient and more informative."Several authors disclosed ties to the biopharmaceutical industry; the study was partially funded by Avid Radiopharmaceuticals and Eli Lilly and Company.Abstract/Full Text (subscription or payment may be required).Sign up for our weekly HealthDay newsletter

Three Trajectories Identified in Preclinical Progression in Alzheimer Disease

Related Stories

Dementia Screening Safe For Families, Trial Finds

Optimal Sleep May Reduce Dementia Risk in Patients With Focal Epilepsy

Cholesteatoma, Tympanic Membrane Perforation Linked to Dementia

Amyloid-Beta-Targeted MAbs Have Little Impact in MCI, Mild Alzheimer Disease Dementia